Last reviewed · How we verify
NCT03254550
PrEP Demonstration Study in Swaziland
NA trial testing PrEP Promotion Package in HIV Negative People Identified at Substantial Risk for HIV Infection in 517 participants. Completed in 2 March 2019.
31 January 2019
Quick facts
| Lead sponsor | Clinton Health Access Initiative Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 517 |
| Start date | 1 August 2017 |
| Primary completion | 31 January 2019 |
| Estimated completion | 2 March 2019 |
| Sites | 6 locations across Eswatini |
Drugs / interventions tested
- PrEP Promotion Package
Conditions studied
- HIV Negative People Identified at Substantial Risk for HIV Infection — all drugs for HIV Negative People Identified at Substantial Risk for HIV Infection →
Sponsor
Clinton Health Access Initiative Inc.
Who can join
16 and older, any sex, with HIV Negative People Identified at Substantial Risk for HIV Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This stepped-wedge cluster-randomized trial is embedded in an 18-month observational cohort study that has the aim to assess the operationalization of oral Pre-Exposure Prophylaxis (PrEP) in Swaziland as an additional HIV combination prevention method among individuals at high risk of HIV infection. The trial aims to determine the effect of a healthcare facility-based PrEP promotion package on the number of clients who take up PrEP.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A stepped-wedge randomized trial and qualitative survey of HIV pre-exposure prophylaxis uptake in the Eswatini population.
Geldsetzer P, Bärnighausen K, Hettema A, McMahon SA, et al · · 2020 · cited 14× · PMID 32967974 · DOI 10.1126/scitranslmed.aba4487
Verify or expand the search:
- PubMed search for NCT03254550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Clinton Health Access Initiative Inc. trials
Trials by the same sponsor.
- NCT06928207 — Private Medicine Retailer-based Trial of Malaria Tests and Conditional Treatment Subsidies Among Patients With Fever · Phase 4 · completed
- NCT04893616 — Cameroon HepB Birth Dose Feasibility Pilot · NA · completed
- NCT04048629 — Impact of Point-of-care (POC) Viral Load (VL) Testing During Pregnancy in Zimbabwe · NA · completed
- NCT03263182 — Impact of the Safe Childbirth Checklist in Luapula Province of Zambia Province of Zambia · completed
- NCT02909218 — MaxART: Early Access to ART for All in Swaziland · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03254550 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinton Health Access Initiative Inc.
- Last refreshed: 11 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03254550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing